Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202011026 A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202012007 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202012035 Development of stem cell culture technology in vitro - Hair follicle and skin sample collection Dermatosis/skin disease SHH Dermatology

Woan-Ruoh Lee

 02-6620-2589
N202012037 SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Breast Cancer SHH Hematology and Oncology

Wei-Hong Cheng

 02-6620-2589
N202101017 Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy Interstitial lung disease SHH Pulmonary Medicine

Tzu-Tao Chen

 02-6620-2589
N202102065 Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) Breast Cancer SHH Hematology and Oncology

Tsu-Yi Chao

 02-6620-2589
N202102073 Prospective Observational Cohort Study of Patients with Moderate to Severe Chronic Plaque Psoriasis in Taiwan Chronic Plaque Psoriasis SHH Dermatology

Woan-Ruoh Lee

 02-6620-2589
N202104068 A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients with Advanced Solid Malignancies Solid tumors SHH Hematology and Oncology

Wei-Hong Cheng

 02-6620-2589
N202108070 An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202110016 A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Proliferative Lupus Nephritis SHH Allergy, Immunology and Rheumatology

Yu-Sheng Chang

 02-6620-2589
1 2 3 4 5 6 / 6

TOP